Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 477-483

  Jager, N G L ^a   Rosing, H ^a   Schellens, J H M ^b,c   Linn, S C ^b   Beijnen, J H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Endoxifen; Metabolite levels; Tamoxifen; Therapeutic drug monitoring

Indexed keywords

ADULT; AGED; AMBULATORY CARE; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 84894036918     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2826-1     Document Type: Article

References (32)

1. Peng J, Sengupta S, Jordan VC (2009) Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 9:481-499
2. Shao W, Brown M (2004) Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6:39-52
3. Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
4. Beelen K, Zwart W, Linn SC (2012) Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9:529-541. doi: 10.1038/nrclinonc.2012.121
5. Bratherton DG, Brown CH, Buchanan R et al (1984) A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50:199-205
6. Ward HW (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Brit Med J 1:13-14
7. Teunissen SF, Rosing H, Seoane MD et al (2011) Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J Pharm Biomed Anal 55:518-526
8. Murdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
9. O'Neill M, Heckelman P, Koch C, Roman K (2006) The Merck Index, 14th edn. 1554 pp
10. Katzenellenbogen BS, Norman MJ, Eckert RL et al (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119
11. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS (1985) Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem 22:589-596
12. Robertson DW, Katzenellenbogen JA, Long DJ et al (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13
13. Jordan VC, Haldemann B, Allen KE (1981) Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 108:1353-1361
14. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478
15. Johnson MD, Zuo H, Lee KH et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159
16. Lu WJ, Desta Z, Flockhart DA (2012) Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 131:473-481. doi: 10.1007/s10549-011-1428-z
17. Wu X, Hawse JR, Subramaniam M et al (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727. doi: 10.1158/0008-5472.CAN-08-3933
18. Hawse JR, Subramaniam M, Cicek M et al (2013) Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One 8:e54613. doi: 10.1371/journal.pone.0054613
19. Gong IY, Teft W, Ly J et al (2013) Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat 450:61-69. doi: 10.1007/s10549-013- 2530-1
20. Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725
21. Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74
22. Lien E, Søiland H, Lundgren S (2013) Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Res Treat. doi: 10.1007/s10549-013-2677-9
23. Jager NGL, Rosing H, Linn SC et al (2012) Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. Breast Cancer Res Treat 133:793-798. doi: 10.1007/s10549-012-2000-1
24. Lønning P, Lien E (1992) Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327-358
25. Adam H, Patterson J, Kemp J (1980) Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 64:761-764
26. Fabian C, Sternson L, Barnett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 64:765-773
27. Teunissen SF, Jager NGL, Rosing H et al (2011) Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr, B Anal Technol Biomed Life Sci 879:1677-1685
28. Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation. USA Food and Drug Administration, pp 4-10
29. European Medicines Agency (2011) Guideline on bioanalytical method validation. European Medicines Agency, pp 4-10
30. Irvin WJ Jr, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a Multicenter Study. J Clin Oncol 29:3232-3239
31. Barginear MF, Jaremko M, Peter I et al (2011) Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the Antiestrogenic Activity Score. Clin Pharmacol Ther 90:605-611
32. Sismondi P, Biglia N, Volpi E et al (1994) Tamoxifen and endometrial cancer. Ann New York Acad Sci 734:310-321